Skip to Content
Merck
All Photos(4)

Key Documents

R116

Sigma-Aldrich

Riluzole

≥98% (HPLC), solid, glutamate release inhibitor

Synonym(s):

2-Amino-6-(trifluoromethoxy)benzothiazole

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C8H5F3N2OS
CAS Number:
Molecular Weight:
234.20
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

product name

Riluzole, solid

form

solid

originator

Sanofi Aventis

SMILES string

Nc1nc2ccc(OC(F)(F)F)cc2s1

InChI

1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)

InChI key

FTALBRSUTCGOEG-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Glutamate release inhibitor; anticonvulsant

Features and Benefits

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Skull and crossbones

Signal Word

Danger

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 2 Oral

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Maurizio Anzini et al.
Journal of medicinal chemistry, 53(2), 734-744 (2009-12-03)
A series of amidine, thiourea, and guanidine derivatives of 2-amino-6-(trifluoromethoxy)benzothiazole termed 2, 3, and 4, respectively, and structurally related to riluzole, a neuroprotective drug in many animal models of brain disease, have been synthesized. The biological activity of compounds 2a-e
Ryan S Phillips et al.
eLife, 11 (2022-07-08)
Previously our computational modeling studies (Phillips et al., 2019) proposed that neuronal persistent sodium current (INaP) and calcium-activated non-selective cation current (ICAN) are key biophysical factors that, respectively, generate inspiratory rhythm and burst pattern in the mammalian preBötzinger complex (preBötC)
Michael G Fehlings et al.
Journal of neurosurgery. Spine, 17(1 Suppl), 151-156 (2012-09-19)
In the immediate period after traumatic spinal cord injury (SCI) a variety of secondary injury mechanisms combine to gradually expand the initial lesion size, potentially leading to diminished neurological outcomes at long-term follow-up. Riluzole, a benzothiazole drug, which has neuroprotective
Gwen Schwartz et al.
Progress in brain research, 137, 177-190 (2002-11-21)
Traumatic spinal cord injury is a consequence of a primary mechanical insult and a sequence of progressive secondary pathophysiological events that confound efforts to mitigate neurological deficits. Pharmacotherapy aimed at reducing the secondary injury is limited by a narrow therapeutic
Mark C Bellingham
CNS neuroscience & therapeutics, 17(1), 4-31 (2010-03-20)
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neurodegenerative disease of adults which preferentially attacks the neuromotor system. Riluzole has been used as the only approved treatment for amyotrophic lateral sclerosis since 1995, but its mechanism(s) of action in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service